Danaher Corporation (DHR)

NYSE · Washington, D.C., USA · Founded 1969 · CEO Julie Sawyer Montgomery

Valuation summary

$159.04 fair value versus $227.56 in the market, a difference of -30.1%. Rated Sell.

Fair value per share$159.04
Current share price$227.56
Upside / downside-30.1%
Bear case$102.28
Bull case$238.73
Discount rate (WACC)8.9%
Terminal growth2.60%
Market capitalisation$160B
EV / Sales7.1x

About Danaher Corporation

Founded in 1969 as a real estate trust and rebuilt as an industrial conglomerate by the Rales brothers. Rainer Blair, CEO from 2020, handed over on 1 October 2026 to Julie Sawyer Montgomery, who joined Danaher in 2017. Danaher has spent the last decade transforming itself into a pure life sciences and diagnostics company, spinning off its industrial businesses as Fortive and Veralto. The Danaher Business System — a rigorous continuous-improvement methodology applied to every acquisition — is the operational core of the company and is widely imitated.

Investment case

  • Cytiva and Pall give Danaher a leading position in bioprocessing, the equipment used to manufacture biologic drugs.
  • Around 75% of revenue is recurring consumables and services.
  • The Danaher Business System has a long, verifiable record of improving acquired businesses.

Key risks

  • Bioprocessing demand fell sharply as customers worked through pandemic-era inventory, and the recovery has been slow.
  • China is a meaningful market and remains weak.
  • Valuation still reflects a premium quality rating that recent growth has not supported.

Recent developments

Revenue by segment

Biotechnology27%
Life Sciences30%
Diagnostics43%

Five-year forecast

RevenueFree cash flow
Year 1$26.9B$7.9B
Year 2$28.4B$8.1B
Year 3$29.9B$8.2B
Year 4$31.6B$8.4B
Year 5$33.3B$8.6B

What the street says

Long regarded as one of the best-run companies in healthcare. The bear case centres on bioprocessing normalisation timing, and the October 2026 handover from Rainer Blair to Julie Sawyer Montgomery adds a leadership transition to watch.

Comparable companies: NVO · GILD · AMGN · BMY · PFE · GSK · NVS · TMO

Open the interactive model, price chart and sensitivity grid →